In particular, STAT3 activation has been reported in nearly 70% of solid and hematological tumors, including multiple myeloma, several lymphomas and leukemia, breast cancer, head and neck cancer, prostate cancer, ovarian carcinoma, melanoma, renal carcinoma, colorectal carcinoma and thymic epithelial tumors [31]. This evidence concerns the gene STAT3 and breast carcinoma.